LV-CMV-IFNγ significantly inhibited the replication of adenovirus ex vivo, suggesting that the persistent and protective co-infection with recombinant interferon-γ lentivirus could be a potential approach for studying an alternative therapy of both DNA and RNA viral diseases, such as severe hepatitis B and C and HIV/AIDS. This evidence concerns the gene IFNG and viral infectious disease.